HIRSCH RUSSELL C 4
4 · AVEO PHARMACEUTICALS INC · Filed Dec 3, 2010
Insider Transaction Report
Form 4
HIRSCH RUSSELL C
Director
Transactions
- Sale
Common Stock
2010-12-02$14.93/sh−317,572$4,739,984→ 1,270,142 total(indirect: By Prospect Venture Partners II, L.P.) - Sale
Common Stock
2010-12-02$14.93/sh−4,836$72,181→ 19,341 total(indirect: By Prospect Associates II, L.P.)
Footnotes (3)
- [F1]The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.50 to $15.00, inclusive. The reporting person undertakes to provide AVEO Pharmaceuticals, Inc., any security holder of AVEO Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
- [F2]Held by Prospect Venture Partners II, L.P. Alexander E. Barkas, Ph.D., David Schnell, M.D. and Russell C. Hirsch, M.D., Ph.D., the managing members of Prospect Management Co. II, LLC, the General Partner of Prospect Venture Partners II, L.P., share voting and investment power over the shares held by Prospect Venture Partners II, L.P., but disclaim beneficial ownership, except to the extent of their pecuniary interest therein.
- [F3]Held by Prospect Associates II, L.P. Alexander E. Barkas, Ph.D., David Schnell, M.D. and Russell C. Hirsch, M.D., Ph.D., the managing members of Prospect Management Co. II, LLC, the General Partner of Prospect Associates II, L.P., share voting and investment power over the shares held by Prospect Associates II, L.P., but disclaim beneficial ownership, except to the extent of their pecuniary interest therein.